Zenas Biopharma Inc (ZBIO)

May 13, 2025, 4:20 PM EDT - 21 hours ago

Zenas BioPharma Investors: Cohen Milstein Highlights June 16 Deadline to Seek Lead Plaintiff Role in Securities Lawsuit

May 5, 2025, 2:48 PM EDT - 8 days ago

Cohen Milstein Reminds Zenas BioPharma (ZBIO) Investors of Opportunity to Lead Securities Fraud Suit

May 3, 2025, 8:27 AM EDT - 11 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

May 1, 2025, 3:08 PM EDT - 12 days ago

Cohen Milstein Seeks Investors to Lead Suit to Hold Zenas BioPharma (ZBIO) Accountable for IPO-Related Fraud

Apr 22, 2025, 10:37 AM EDT - 22 days ago

Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses

Apr 21, 2025, 12:33 PM EDT - 23 days ago

Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses

Apr 17, 2025, 8:00 PM EDT - 26 days ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Zenas BioPharma, Inc. (ZBIO)

Apr 17, 2025, 4:20 PM EDT - 26 days ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 7, 2025, 3:08 PM EDT - 5 weeks ago

Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst

Apr 7, 2025, 7:05 AM EDT - 5 weeks ago

Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

Mar 20, 2025, 2:54 PM EDT - 7 weeks ago

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

Mar 17, 2025, 7:05 AM EDT - 2 months ago

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

Feb 5, 2025, 7:05 AM EST - 3 months ago

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

Jan 28, 2025, 8:00 AM EST - 3 months ago

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

Nov 12, 2024, 7:10 AM EST - 6 months ago

Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 12, 2024, 7:05 AM EST - 6 months ago

Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Nov 7, 2024, 7:05 AM EST - 6 months ago

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

Sep 19, 2024, 4:15 PM EDT - 8 months ago

Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering

Sep 14, 2024, 5:00 AM EDT - 8 months ago

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

BCAX GLXG MBX TDTH XCH

Sep 12, 2024, 10:37 PM EDT - 8 months ago

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Sep 7, 2024, 1:25 AM EDT - 8 months ago

U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows

BCAX BIOA PMAX PTHL

Aug 26, 2024, 11:11 AM EDT - 9 months ago

Zenas BioPharma Seeks IPO For Inflammatory Treatment Trials

Aug 24, 2024, 5:00 AM EDT - 9 months ago

U.S. IPO Weekly Recap: WeRide Delays Its IPO As Pipeline Gets A Boost

AZI RITR TDTH WOK